GlassScriptPhysician profile
Avinash Aravantagi
NPI 1154577336
$44,861.25
in general payments reported to CMS, 2019-2025
31 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $405 · 2021: $540 · 2022: $895 · 2023: $936 · 2024: $16K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $7,314 · Food and Beverage: $2,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,250.00 |
| Travel and Lodging | $7,313.66 |
| Food and Beverage | $2,901.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $40,224.35 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,668.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.92 | 2019-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $214.28 | 2019-2024 | Linzess |
| Pfizer INC. | $185.45 | 2019-2025 | |
| Janssen Biotech, INC. | $169.89 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $158.88 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $147.75 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $62.74 | 2019-2021 | |
| Genzyme Corporation | $62.27 | 2023-2024 | |
| Qol Medical, LLC | $60.25 | 2021-2023 | Sucraid |
| Allergan, INC. | $59.44 | 2019 | |
| Ucb, INC. | $59.42 | 2019-2020 | |
| Daiichi Sankyo INC. | $47.99 | 2021 | |
| Lilly USA, LLC | $46.72 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.76 | 2019-2022 | |
| Redhill Biopharma INC. | $43.01 | 2021-2022 | |
| Celgene Corporation | $40.41 | 2021-2023 | Zeposia |
| Medtronic, INC. | $39.16 | 2022 | |
| Intercept Pharmaceuticals, INC. | $38.40 | 2021-2025 | |
| Ardelyx, INC. | $30.33 | 2025 | Ibsrela |
| Evoke Pharma, INC. | $19.48 | 2025 | |
| Albireo Pharma, INC. | $18.13 | 2024 | Bylvay |
| Dynavax Technologies Corporation | $17.68 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $17.33 | 2025 | Lockado |
| Novo Nordisk INC | $16.96 | 2025 | Wegovy |
| Celltrion USA INC. | $16.84 | 2025 | Vegzelma |
| Alfasigma USA, INC. | $16.48 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.12 | 2025 | Iqirvo |
| Amgen INC. | $14.19 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $13.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Aravantagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.